ZA200100867B - Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P. - Google Patents

Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P. Download PDF

Info

Publication number
ZA200100867B
ZA200100867B ZA200100867A ZA200100867A ZA200100867B ZA 200100867 B ZA200100867 B ZA 200100867B ZA 200100867 A ZA200100867 A ZA 200100867A ZA 200100867 A ZA200100867 A ZA 200100867A ZA 200100867 B ZA200100867 B ZA 200100867B
Authority
ZA
South Africa
Prior art keywords
methyl
imidazol
dimethylamino
pyrazol
chloro
Prior art date
Application number
ZA200100867A
Other languages
English (en)
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of ZA200100867B publication Critical patent/ZA200100867B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200100867A 1998-08-07 2001-01-31 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P. ZA200100867B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Publications (1)

Publication Number Publication Date
ZA200100867B true ZA200100867B (en) 2001-08-16

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200100867A ZA200100867B (en) 1998-08-07 2001-01-31 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P.

Country Status (26)

Country Link
US (1) US6518295B1 (pt)
EP (1) EP1103243B1 (pt)
JP (1) JP2002522359A (pt)
KR (1) KR100558506B1 (pt)
CN (1) CN1151789C (pt)
AR (1) AR019999A1 (pt)
AT (1) ATE257379T1 (pt)
AU (1) AU754124B2 (pt)
BR (1) BR9912807A (pt)
CA (1) CA2339661C (pt)
CO (1) CO5080747A1 (pt)
CZ (1) CZ292065B6 (pt)
DE (1) DE69914085T8 (pt)
DK (1) DK1103243T3 (pt)
ES (2) ES2150378B1 (pt)
HU (1) HUP0105428A3 (pt)
IL (1) IL141295A0 (pt)
NO (1) NO20010634L (pt)
NZ (1) NZ509645A (pt)
PL (1) PL193802B1 (pt)
PT (1) PT1103243E (pt)
RU (1) RU2223116C2 (pt)
TR (1) TR200100378T2 (pt)
TW (1) TW445259B (pt)
WO (1) WO2000007542A2 (pt)
ZA (1) ZA200100867B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
CN101065014A (zh) * 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
AU2007209381A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
JP5064511B2 (ja) 2006-11-02 2012-10-31 エフ.ホフマン−ラ ロシュ アーゲー 痕跡アミン関連受容体調節剤としての置換2−イミダゾール
RU2456281C2 (ru) 2006-11-16 2012-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные 4-имидазолы, способ их получения и их применение
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
ATE509628T1 (de) 2006-12-13 2011-06-15 Hoffmann La Roche Neue 2-imidazole als liganden für trace amine associated receptors (taar)
BRPI0806940A2 (pt) 2007-02-02 2014-05-06 Hoffmann La Roche 2-amino-oxazolinas como ligantes taar1 para distúrbios do snc
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
AU2008270445A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (TAARs)
MX2009013745A (es) 2007-07-03 2010-01-26 Hoffmann La Roche 4-imidazolinas y su uso como antidepresivos.
CN101765587A (zh) 2007-07-27 2010-06-30 弗·哈夫曼-拉罗切有限公司 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20100291151A1 (en) * 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
CA2273810A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders
JP2001508412A (ja) * 1996-12-02 2001-06-26 メルク シヤープ エンド ドーム リミテツド 認識障害の治療のためのnk−1受容体拮抗薬の使用
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
KR100558506B1 (ko) 2006-03-07
DK1103243T3 (da) 2004-05-03
CN1317966A (zh) 2001-10-17
CA2339661C (en) 2006-10-17
ATE257379T1 (de) 2004-01-15
HUP0105428A3 (en) 2003-01-28
AU754124B2 (en) 2002-11-07
ES2213380T3 (es) 2004-08-16
ES2150378B1 (es) 2001-07-01
CA2339661A1 (en) 2000-02-17
AU5422999A (en) 2000-02-28
JP2002522359A (ja) 2002-07-23
NZ509645A (en) 2003-01-31
DE69914085D1 (de) 2004-02-12
EP1103243A2 (en) 2001-05-30
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
DE69914085T2 (de) 2004-11-25
EP1103243B1 (en) 2004-01-07
NO20010634L (no) 2001-04-06
PL193802B1 (pl) 2007-03-30
TW445259B (en) 2001-07-11
AR019999A1 (es) 2002-03-27
WO2000007542A3 (es) 2000-05-11
NO20010634D0 (no) 2001-02-06
CZ2001412A3 (cs) 2001-08-15
WO2000007542A2 (es) 2000-02-17
HUP0105428A2 (hu) 2002-05-29
BR9912807A (pt) 2001-10-16
RU2223116C2 (ru) 2004-02-10
DE69914085T8 (de) 2005-04-21
PT1103243E (pt) 2004-05-31
CN1151789C (zh) 2004-06-02
CZ292065B6 (cs) 2003-07-16
IL141295A0 (en) 2002-12-01
TR200100378T2 (tr) 2001-06-21
ES2150378A1 (es) 2000-11-16
KR20010079616A (ko) 2001-08-22
CO5080747A1 (es) 2001-09-25

Similar Documents

Publication Publication Date Title
ZA200100867B (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P.
DE69921157T2 (de) Verwendungsmethoden und zusammenstellungen die einen dopaminewiederaufnahmeinhibitor enthalten
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
EP1633400A2 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20080221078A1 (en) Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
US20110021530A1 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
SG11201808003RA (en) Bromodomain inhibitors
CA2859619C (en) Bromodomain inhibitors
SG11201408261UA (en) Syringe
CN101903374A (zh) 作为met激酶抑制剂的2-苄基哒嗪酮衍生物
SG11201804100UA (en) Pharmaceutical composition comprising a potent inhibitor of urat1
JP2024114905A (ja) Vmat2インヒビター化合物、上記化合物に関する組成物および方法
JP2008518896A (ja) ニコチン性アセチルコリンα7受容体アンタゴニストの組合せ剤
HUE029485T2 (en) New cyclohexylamine derivatives with B2 adrenergic agonist and M3 muscarinic antagonist activity
SG11201908235RA (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
SG11201806424TA (en) Therapeutic compounds
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201906767XA (en) Estrogen receptor modulators
SG11201805049TA (en) Pellets used in cell culture and methods of making thereof
TWI419689B (zh) 用於治療薩羅霍症(Sialorrhoea)之醫藥組合物
CN101472586A (zh) 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法
EP1254660B1 (en) Methods for using pyrrole derivatives against obsessive compulsive disorder
SG11201408076WA (en) Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
CN102227227B (zh) 包含吡啶并[4,3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合